Fig. 4

K3016 SP1: A1V mutant is resistant to BVM analog. HEK-293 T cells were transfected with the HIV-1 subtype C K3016 WT and K3016 SP1: A1V mutant. Cells were treated with 10 nM and 100 nM of BVM analog CV-8612 or with DMSO only. a The virion-associated CA and CA-SP1 were detected by immunoblotting. % CA-SP1 accumulation is presented in the graphs. The gel image shown here is representative of three independent experiments. b The viruses produced from the BVM analogs-treated HEK-293T cells were quantified, and TZM-bl cells were infected with p24 normalized viruses for 48 h. The cells were lysed and assayed for luciferase activity. Quantitative data for levels of infectivity relative to the DMSO control-treated sample is shown. Error bars indicate standard deviations from three independent experiments. The asterisks indicate significant differences (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001) and ns indicates not significant. c The HUT-R5 T-cells were transfected with the HIV-1 subtype C molecular clone K3016 WT and K3016 SP1: A1V mutant. Transfected cells were propagated in the presence of 10 and 100 nM of the BVM analog CV-8612 or with DMSO only. Virus replication was monitored by quantifying HIV-1 p24 concentration in the culture supernatant, and the replication profile was represented as a graph